A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

Study on Eosinophilic Esophagitis and DUPIXENT® Use

Recruiting
1 year or above
All
Phase N/A
350 participants needed
28 Locations

Study Overview

This observational research study is to better understand patients with eosinophilic esophagitis (EoE) who have recently been prescribed DUPIXENT® (dupilumab).

The purpose of this research study is to look at how DUPIXENT is used in normal care of patients with EoE.

Possible benefits to others include a better understanding of EoE and helping to inform research and clinical trial design leading to treatment decisions in this patient population going forward.

Patient questionnaires will measure the following:

  • How EoE makes one feel
  • EoE signs and/or symptoms, eg, how difficult it is to swallow
  • How EoE affects quality-of-life
  • How EoE impacts aspects of daily life
  • How EoE symptoms have changed throughout the study

Eligibility Criteria

You may be eligible for this study if you meet the following criteria:

  • Conditions: Eosinophilic Esophagitis (EoE)
  • Age: 1 year or above
  • Gender: All

Key Inclusion Criteria:

  1. Initiating treatment with DUPIXENT® for EoE according to the USPI
  2. Participants aged ≥12 years and caregivers or legal guardians of participants aged <12 years must be able to understand and complete registry-related questionnaires

Key Exclusion Criteria:

  1. Patients who have a contraindication to DUPIXENT® according to the USPI
  2. Treatment with DUPIXENT® within the 6 months prior to the screening assessment
  3. Participation in an ongoing interventional study on or within 6 months of the baseline assessment. Once enrolled in registry, participation is allowed in other ongoing studies (at the discretion of the registry investigator)

NOTE: Other protocol defined inclusion/exclusion criteria apply

This study investigates eosinophilic esophagitis in patients who are being treated with an investigational medication as part of their standard care. The purpose is to gather more information about these patients and their experiences.

The study focuses on understanding how the investigational medication is used in everyday care for eosinophilic esophagitis. It looks at various aspects such as the impact on quality of life and changes in symptoms over time.

  • Who can participate: Participants aged 12 years and older who are starting treatment with the investigational medication for eosinophilic esophagitis can join. Caregivers of participants under 12 must be able to complete questionnaires.
  • Study details: Participants will complete questionnaires about their feelings, symptoms, and quality of life related to eosinophilic esophagitis. This helps understand the condition's impact on daily life.
Updated on 20 Apr 2026. Study ID: NCT06693531

Find a study site near you

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
United States Only: Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language